- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
The Food and Drug Administration (FDA) has granted 510(k) clearance for FemChec®, a modality that generates natural contrast for use in ultrasound imaging of fallopian tubes. This imaging may potentially be utilized to confirm the success of FemBloc®, a non-surgical approach to permanent birth control that is currently being evaluated in a clinical trial.
Using an intrauterine catheter, clinicians can employ FemChec to provide a continuous contrast media stream of alternating saline and air to enhance ultrasound visualization of the fallopian tubes with or without the uterine cavity, according to Femasys, the developer of FemChec and FemBloc.
The recently FDA-cleared FemChec®, which generates natural contrast for use in ultrasound imaging of fallopian tubes, may potentially play a key diagnostic role in confirming the results of a non-surgical approach to permanent birth control (FemBloc®) that is currently being evaluated in a clinical trial. (Photo courtesy of Adobe Stock.)
The company said the combination of natural contrast and ultrasound may provide a viable alternative to traditional X-ray and corresponding radiation exposure for evaluating fallopian tubes.
“FemChec is an essential part of our suite of women’s health products as it fortifies our position to provide safe and technologically advanced diagnostic and therapeutic solutions addressing women’s health care needs,” noted Kathy-Lee Sepsick, the chief executive officer and founder of Femasys.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
